Table 4 Treatment related characteristics affecting distant metastasis and progression-free survival outcomes.

From: Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients

Characteristics	Distant Metastasis Free Survival (DMFS)						Progression Free survival (PFS)
	Univariate	Multivariate analysis					Univariate	Multivariate analysis
	p-value	Patients	Events	HR	95% CI	Test C-index	p-value	Patients	Events	HR	95% CI	Test C-index
IRS Post-surgical Group
Group I	< 0.001	342	78	0.40	0.225–0.703	70%	< 0.001	342	113	0.34	0.212–0.554	70%
Group I-II	0.038	342	78	1.57	0.827–2.974	66%	0.033	342	113	0.86	0.491–1.519	70%
Group II	0.068	342	78	2.16	1.21–3.83	65%	0.020	342	113	1.25	0.736–2.13	70%
Treatment Modality
Trimodality	0.246	390	94	0.69	0.419–1.14	64%	0.321	342	113	0.82	0.52–1.284	68%
Surgery and Chemotherapy	0.015	390	94	0.65	0.386–1.106	64%	0.004	342	113	0.72	0.44–1.191	69%
Radio and Chemotherapy	0.251	390	94	1.19	0.673–2.119	62%	0.509	342	113	0.98	0.585–1.652	69%
Surgery alone	0.028	390	94	1.09	0.633–1.89	62%	0.012	342	113	1.04	0.587–1.825	70%
Surgery and Radiotherapy	0.907	390	94	2.19	1.192–4.01	64%	0.498	342	113	2.01	1.0783–3.761	69%
Chemotherapy Use	0.026	390	94	0.61	0.382–0.9708	66%	0.001	342	113	0.52	0.315–0.859	70%
Category of Chemotherapy
Cyclo based	0.572	269	59	1.40	0.72–2.69	64%	0.427	241	74	1.27	0.721–2.218	71%
Cyclo and Anthracycline based	0.231	269	59	0.87	0.431–1.75	63%	0.021	241	74	0.56	0.291–1.078	69%
Ifo and Anthracycline based	0.843	269	59	0.92	0.434–1.94	63%	0.704	241	74	0.89	0.446–1.77	70%
Anthracycline only based	0.243	269	59	1.13	0.414–3.087	63%	0.139	241	74	2.73	1.154–6.475	70%
Cyclo and Ifo and Anthracycline based							0.200	241	74	0.40	0.098–1.659	70%
Ifo based
Timing of Chemotherapy
Adjuvant	0.006	371	91	0.62	0.394–0.98	64%	0.001	334	110	0.79	0.515–1.208	68%
Both pre and Post surgery	0.223	371	91	0.31	0.043–2.27	58%	0.265	334	110	0.61	0.191–1.963	70%
Primary modality	0.056	371	91	1.36	0.796–2.33	60%	0.366	334	110	0.91	0.541–1.517	69%
Neoadjuvant							0.958	334	110	0.74	0.294–1.84	70%
Response to chemotherapy
Complete response (CR)	0.017	387	94	0.29	0.104–0.7906	63%	0.002	339	113	0.25	0.11–0.589	69%
Disease progression (PD)	< 0.001	387	94	4.36	2.46–7.706	67%	< 0.001	339	113	3.50	2.002–6.127	71%
Not available (N/A)	0.628	387	94	1.10	0.580–2.07	61%	0.539	339	113	0.67	0.34–1.295	69%
Partial response (PR)							0.619	339	113	0.91	0.498–1.665	69%
No response (NR)

^aBold = significant values (p < 0.05); Cyclo: Cyclophosphamide; Ifo: Ifosfamide; VA: Vincristine, Actinomycin-D. For the multivariate models, each variable was adjusted to the following set of covariates: DMFS analysis: Age, Head/Neck (Non PM) tumor site, GU (B/P) tumor site, and IRS risk group; PFS analysis: Age, Head/Neck (Non PM) tumor site, IRS Post-Surgical Group-I, IRS Post-Surgical Group-II and IRS risk group. Empty rows correspond to covariates that were not entered into the model because they were either explained by other covariates or did not meet the model inclusion criteria (due to small number of events or other reasons - see Methodology section for details).

Back to article page

Table 4 Treatment related characteristics affecting distant metastasis and progression-free survival outcomes.

Search

Quick links